TOPAMAX (topiramate) by Johnson & Johnson is cytochrome p450 3a4 inducers [moa]. First approved in 1998.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
TOPAMAX (topiramate) is an oral small-molecule anticonvulsant approved in 1998 that works as a cytochrome P450 3A4 inducer. While originally indicated for epilepsy, it has been widely used off-label for migraine prevention and weight management, making it a versatile therapeutic agent across multiple indications.
As LOE approaches, commercial teams are transitioning from growth strategies to defensive positioning and cost management, likely resulting in smaller brand teams focused on retention.
Cytochrome P450 3A4 Inducers
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users
Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine
Worked on TOPAMAX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TOPAMAX offers limited career growth opportunity given its LOE status and zero linked job postings; roles are primarily defensive and focused on protecting market share against generics. This product is better suited for early-career professionals seeking stability or experienced managers with turnaround expertise rather than high-growth trajectory.